383MO Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase Ia/b EMBER study
Authors:
- 20 October 2023
- journal article
- abstracts
- Published by Elsevier in Annals of Oncology
- Vol. 34, S338-S339